NYSE:BSX

Boston Scientific Corp (BSX)

45.37
+0.32 (0.71%)
as of Oct 20, 2026, 5:33:00 pm Market Open.
102 watching
0
TOP PICK
They make global medical devices. A steady eddy pick and a good way to play healthcare. Their Q4 report sucked, so the stock sold off, but this has outperformed the medical devices and healthcare indexes before Q4. Q4 was a hiccup, so it's now a buying opportunity or around $40. (Analysts’ price target is $49.14)
BUY ON WEAKNESS
Changing demographics? He has a model price of $45.83 per share -- right around current prices. A move higher in the market could take it to $61. He would wait thru the next earnings announcement. It is not cheap here. He would wait for a pullback before buying in.
PAST TOP PICK

(A Top Pick Sep 18/18, Up 11%) They make heart pacers and have expanded into joint replacements through acquisitions. It was poorly managed, but has turned around in the past three years. He's trimmed around $42 to be Pfizer. However, all medical stocks face US politicians bashing them during elections. So, load up on health stocks and do well after the vote.

BUY
Since 2014, management has executed very good 7-9% organic EPS growth while compressing margins on the cost side. Last quarter, though, they had a hiccup with their Watchman device, but the market forgave them because of BSX's track record. Happy to own it. They report next week. If they miss, expect volatility.
BUY
They've done a good job turning around in the past 7 years with a new CEO. Margins will continue to rise with high single-digit growth. Legal settlements and tax issues are behind them, thus freeing up their cash. This is a big holding for him.
HOLD
Likes 2-year time horizon. A stellar performer. Executing on top and bottom line. An example of how margins should be. Couple of new products are coming out, and one of best organic growth profiles in the sector. This quarter was the first hiccup in a long time, but the market gave them a pass. He'll give them another quarter to prove themselves.
BUY
BSX-N vs. TFX-N. TFX-N is a smaller high growth company. BSX-N is a market leader but recovering from a few years of bad management. He has a low $40s target in a year. He would stick with it.
BUY
He still loves this name. You can still buy it in the low $30s and he has a target of the low $40s. They are making acquisitions.
BUY

He sold shares in Medtronics (MDT-N) to buy this, which he sees as more of a turnaround play. He sees higher growth prospects in their more targeted business model.

TOP PICK

The company has raised its growth rate from 5-to-7% to 7-to-10% range. This is a strong turnaround, and he is excited about medical stocks doing better. Yield 0%. (Analysts’ price target is $38.78)

BUY

He likes it. They are in cardiac arrhythmia management and cardiology devices. Best in class organic growth. They made 8 acquisitions over the past year or so. Might be a target for an acquisition. One of his favorites option candidates.

BUY

On the 5 year chart you can see it is in an uptrend. It is quite tradable. It began to find a lid just under $30. Buy in the low $20s and sell in the high $20’s. Don’t own it for the long run.

HOLD

No dividend, focussed on cardiac equipment like pacemakers. Have made many acqusitions in past years. Fabulous management. Have driven cost synergies consistently. Beat estimates recently. Forward earnings are 20x. A solid hold.

COMMENT

If you own healthcare providers, especially in the hospital supply area, they have been great stocks for a long time. We are all getting older and need more help. Prefers Medtronic (MDT-N) a little better. However, this is another dividend growth story, so you can’t go wrong here.

HOLD

An extraordinarily well-run company. Great organic growth. A leader in the cardiac rhythm management, and have done that principally organically. The new management in 2012 streamlined operations, became very efficient and enhanced margins on the back of that. This is a company that he wants to continue to own.

Showing 46 to 60 of 74 entries